NAD+ and Frailty in Older Adults: New Human Evidence

Key Finding Each 1 µmol/L increase in whole-blood NAD+ was associated with 13% lower odds of frailty in community-dwelling adults aged 65 and older, though the association weakened after adjusting for hematocrit.

A new study from the Itabashi Longitudinal Study on Aging adds human observational data to the question of whether NAD+ levels relate to frailty in older adults. Published in GeroScience, the analysis examined whole-blood NAD+ concentration and frailty status in 529 community-dwelling adults aged 65 and older in Tokyo [PMID 42744962].

What the study examined

NAD+ (nicotinamide adenine dinucleotide) is central to energy metabolism, redox reactions, and cellular signaling. Its decline with age has been documented in animal models and some human tissues, but direct evidence linking circulating NAD+ concentrations to frailty — a clinical state of decreased physiological reserve — has been limited.

The Itabashi study assessed frailty using the revised Japanese Cardiovascular Health Study criteria, which evaluate weight loss, fatigue, physical activity, gait speed, and grip strength. Among the 529 participants (54.3% women), 32 (6.0%) met the criteria for frailty.

The association

Median whole-blood NAD+ concentration was lower among participants with frailty than those without: 24.00 µmol/L versus 25.00 µmol/L (p = 0.007). After adjusting for age, sex, and fasting time, each 1 µmol/L increase in NAD+ concentration was associated with approximately 13% lower odds of frailty (OR 0.871; 95% CI 0.780–0.970; p = 0.013).

The researchers tested the relationship in several ways:

Restricted cubic spline analysis found no clear evidence of nonlinearity
Firth penalized-likelihood logistic regression (which handles rare outcomes) showed the association persisted (OR 0.880; 95% CI 0.782–0.986)
Additional adjustment for hematocrit attenuated the association to non-significance (OR 0.911; 95% CI 0.800–1.034)

The hematocrit question

The attenuation after hematocrit adjustment is methodologically important. Whole-blood NAD+ concentration is influenced by the cellular composition of blood — red blood cells contain NAD+ and their concentration varies between individuals. The authors note that this finding “suggests that blood cell composition may partly explain this association” and call for cell- and tissue-specific NAD+ measurements in future work.

What this means for the NAD+ aging hypothesis

The study provides human observational evidence that lower NAD+ is associated with frailty, consistent with the broader hypothesis that NAD+ decline plays a role in aging-related physiological decline. However, the cross-sectional design, modest effect size, and sensitivity to hematocrit adjustment mean these data should be read as suggestive rather than confirmatory.

What would strengthen the case: longitudinal studies tracking NAD+ levels and frailty status over time in the same individuals, and ultimately interventional trials testing whether NAD+ precursors (such as NR or NMN) affect frailty progression in older adults with low baseline NAD+.

For a broader overview of mitochondrial and metabolic signaling compounds, visit the Research Protocols reference archive.